- This Post has 0 replies, 1 voice, and was last updated 1 year, 3 months ago by
.
-
Post
-
Multiple myeloma is the second most common hematological malignancy. It is defined by the presence of monoclonal plasma cells capable of producing a monoclonal paraprotein causing clinical abnormalities such as anemia, renal insufficiency, hypercalcemia, or bone lesions.
These are 3 most used medicine with great efficacy in this disease: thalidomide, lenalidomide and bortezomib. Lenalidomide price is big concern. However, advances in supportive care have also contributed to improving patient survival and quality of life through improved dialysis indications, the use of agents such as erythropoietin receptor stimulants and bisphosphonates, and the use of new surgical approaches such as vertebroplasty and kyphoplasty.